Town hall, health offices in Nueva Vizcaya on lockdown due to COVID-19 | Inquirer

Town hall, health offices in Nueva Vizcaya on lockdown due to COVID-19

By: - Correspondent /
/ 01:45 PM August 31, 2020

BAYOMBONG, Nueva Vizcaya –– The town hall and health offices here were placed on lockdown on Monday after some workers were exposed to a coronavirus disease (COVID-19) patient, who later died.

Mayor Ralph Lantion also suspended the operations of these offices, heeding the recommendation of local health officials.

The COVID-19 patient, a 62-year-old woman, was the town’s fourth fatality related to the disease.

Article continues after this advertisement

Nueva Vizcaya now has 52 active COVID-19 cases, government data showed.

FEATURED STORIES

Despite the rising COVID-19 cases and deaths in the province, Gov. Carlos Padilla said they would not return to a stricter modified enhanced community quarantine (MECQ).

“The reclassification of the quarantine status for the province from modified general community quarantine to MECQ is just one of the proposals being considered by the executive committee of the Provincial COVID-19 Task Group. However, it was held in abeyance for the meantime,” Padilla said.

LZB
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the and acknowledge that I have read the .

For more news about the novel coronavirus click
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this

www
globalnation
entertainment
technology
globalnation
TAGS: Bayombong, COVID-19, lockdown, Nueva Vizcaya, Philippine news updates, Regions, Town Hall, workers

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the and acknowledge that I have read the .

© Copyright 1997-2025 | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies.